Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07832383 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor

Name: Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor — clinical trial record (NCT07832383)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorNeurocrine Biosciences

Started2026-10

View on ClinicalTrials.gov ↗

Neurocrine Biosciences

25 trials monitored

See 1 trial at risk

Alzheimer's Disease

1,140 trials monitored

See 62 trials at risk

This study is designed to evaluate the efficacy on improving cognitive performance as well as the safety, tolerability, and pharmacokinetics (PK) of NBI-1117567 administered once daily (QD) in adults with mild to moderate AD who are receiving stable treatment with an acetylcholinesterase inhibitor.

Trial Details

NCT Number	NCT07832383
Lead Sponsor	Neurocrine Biosciences
Conditions	Alzheimer's Disease
Enrollment	135 participants
Start Date	2026-10
Primary Completion	2028-05 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-09-22